RT Journal Article SR Electronic T1 Bevacizumab demonstrates activity in advanced refractory fallopian tube carcinoma JF International Journal of Gynecologic Cancer JO Int J Gynecol Cancer FD BMJ Publishing Group Ltd SP 369 OP 372 DO 10.1111/j.1525-1438.2007.01026.x VO 18 IS 2 A1 N. Arora A1 D. Tewari A1 C. Cowan A1 B. Saffari A1 B. J. Monk A1 R. A. Burger YR 2008 UL http://ijgc.bmj.com/content/18/2/369.abstract AB The targeting of angiogenesis pathways in the treatment of gynecological cancers is an exciting development in cancer therapy. Bevacizumab has been shown to have activity in ovarian cancer through its inhibition of the vascular endothelial growth factor. Fallopian tube carcinoma is a rare malignancy and is often treated in a similar manner as ovarian carcinoma. We present a case of a complete response in a woman with refractory metastatic fallopian tube carcinoma treated with bevacizumab. This report demonstrates the significance of anti-angiogenesis therapy in the treatment of these tumors.